Index

abdominal pregnancy, 81
abortion
  epidemiology, 121
  legal/social issues, 141. See also abortion, legal
    considerations/decisions.
abortion, complications
  continued pregnancy, 140
  hemorrhage, 138–139
  infection, 137
  psychological distress, 139–140
  retained uterine products, 137–138
  uterine perforation, 135–137
abortion, legal considerations/decisions
  Harris v. McRae, 867
  informed consent, 187–188
  Maher v. Roe, 867
  Martinez v. Long Island Jewish Hillside Medical
    Center, 187–188
  patient rights, 186
  Perez v. Park Madison Professional Laboratories,
    Inc., 187–188
  Planned Parenthood v. Casey, 867–868
  primary considerations, 188
  Roe v. Wade, 866–867
  Sheppard-Mobley v. King, 187
  Stenberg v. Carhart, 868
  wrongful pregnancy, 186–187
abortion, medical methods
  ancient/botanical techniques, 133
  methotrexate compound, 135
  mifepristone (RU 486), 133–134
  postcoital contraception, 140–141
  prostaglandin compounds, 134–135
  abortion, surgical procedures
    dilation and evacuation (D & E), vs. curettage, 129
    Laminaria insertion/removal, 129–131
    misoprostol technique, 131
    operative procedure, 131–132
    postoperative procedures/treatment, 132
    preoperative medications, 131
    with ultrasound, 129
    hysterotomy/hysterectomy, 133
    instillation methods, 132–133
    menstrual extraction
      arguments against, 129
      operative procedure, 128–129
      preoperative evaluation
        gestational age assessment, 121
        medical/surgical history, 121–122
        patient counseling, 121, 122–123
    vacuum curettage
      cervical clamping, 126
      dilation, 124, 126–127
      instrument/equipment review, 123
      instrument sterilization procedures, 124
      interpersonal skills of practitioner, 123
      local anesthesia, 124
      operative procedure, 127
      paracervical blockade, 124
      pelvic examination, 123
      postoperative procedures/treatment, 127–128
      pretreatment medications, 123–124
      sedation during, 124–126
abruptio placentae. See placental abruption.
acardiac twins, 332
ACNM (American College of Nurse-Midwives), 788
acute dermal gangrene. See necrotizing fasciitis (NF).
AFE. See amniotic fluid embolism (AFE).
AFI. See amniotic fluid index (AFI).
alcohol abuse, 201. See also illicit drugs/alcohol.
alfentanil, 195–196
alloimmune thrombocytopenia (ATTP). See thrombocytopenia (TTP).
American College of Nurse-Midwives (ACNM), 788
amniocentesis complications
accidental fetal needling, 28–29
amniotic fluid discoloration, 28
blood-tinged amniotic fluid, 27
gestational age, 26
MSAFP elevation, 27
maternal age, 26
maternal infection, 28
neonate orthopedic disorder risk, 29
neonate respiratory risk, 29
study design/evaluation, 26
vaginal leakage/spotting, 28
vs. CVS safety, 32–33
early procedures, 32
laboratory problems, 35–36
in multiple gestation, 34
transabdominal procedure
fluid sample collection, 25
needle gauge/length, 25
patient instructions, 25–26
preparation for, 25
successful/unsuccessful attempts, 26
ultrasonography benefits, 28
amniotic fluid embolism (AFE)
causes of death, 737
clinical symptoms, acute, 737–738
diagnosis, 738–739
etiology, 736
incidence of, 736–737
morbidity/mortality, 736, 738
pathophysiology, 736
treatment, 738, 739
amniotic fluid index (AFI)
AFI/MVP accuracy comparison, 49
obtention method, 49
oligohydramnios thresholds, 49–50
polyhydramnios thresholds, 50
volume as assessment tool, 48–49
volume/perinatal outcome relationship, 49
amphetamine, 201
Amsterdam Surgeon’s Guild, 13–14
anesthesia, obstetric. See obstetric anesthesia.
anticholinergic, 199
antiphospholipid syndrome (APS), 875. See also venous thrombosis (VT).
aortic stenosis
future role, 655
morbidity/mortality, 654–655
pathophysiology, 654
in restrictive atrial septum, 655
in utero aortic valvuloplasty, 655
appendicitis. See under surgery in pregnancy, surgical complications
APS. See antiphospholipid syndrome (APS).
aspirin, low-dose, 200
assisted reproductive technology (ART), 322
asynclitism, 486
ATP (autoimmune thrombocytopenia purpura). See thrombocytopenia (TTP).
Atracurium, 198
ATTP (alloimmune thrombocytopenia), 532–533. See also thrombocytopenia (TTP).
autoimmune thrombocytopenia purpura (ATP). See thrombocytopenia (TTP).
B-hCG measurement, 74–75
B-Lynch suture (Brace suture), 278
Baudelocque, Jean Louis, 258
Benedetti, T. J., 274–275
benign cystic teratomas, 438. See also ovarian tumors.
Bernhardt-Roth syndrome (meralgia paresthetica), 770–771
biophysical profile (BPP)
in intrapartum period, 51
predictive parameters, 50–51
score interpretation, 51
uses of, 50
birth injuries
development disorders and adult disease, 767–768
etiology of, 725–726
grief and mourning, perinatal, 769
trauma, blunt abdominal
fetal risks, 768
incidence of, 768
maternal/fetal assessment, 769
maternal resuscitation, 768
motor vehicle accidents/safety, 768–769
birth injuries, fetal
castration, accidental, 754
cephalohematoma, 745–746
environmental risks/exposures, 765–767
eye injuries, 749–750
facial nerve palsy, 753–754
fetal infection, 758–759
fractures, long bones
in breech/cephalic presentations, 750
clavicle fracture, 751
congenital abnormalities, 750
diagnosis, 750
elective fracture, 750
family counseling, 750–751
incidence/etiology, 750
head and neck injuries, 743
intracranial hemorrhages
clinical associations, 759, 761
clinical indicators, 760–761
incidence of, 759
intracranial bleeding, types of, 759
<table>
<thead>
<tr>
<th>Topic</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>periventricular hemorrhage</td>
<td>759</td>
</tr>
<tr>
<td>subarachnoid bleeding</td>
<td>759–760</td>
</tr>
<tr>
<td>treatment</td>
<td>761</td>
</tr>
<tr>
<td>nerve injury</td>
<td></td>
</tr>
<tr>
<td>femoral neuropathy</td>
<td>771–773</td>
</tr>
<tr>
<td>iatrogenic surgical risk factors</td>
<td>769</td>
</tr>
<tr>
<td>incidence of</td>
<td>769</td>
</tr>
<tr>
<td>isolated</td>
<td>754</td>
</tr>
<tr>
<td>lumbosacral palsy</td>
<td>773–774</td>
</tr>
<tr>
<td>meralgia paresthetica</td>
<td>770–771</td>
</tr>
<tr>
<td>postoperative/postpartum paralysis (POP)</td>
<td>769–770</td>
</tr>
<tr>
<td>upper extremities</td>
<td>774</td>
</tr>
<tr>
<td>overview</td>
<td>743</td>
</tr>
<tr>
<td>perineal injuries</td>
<td>754</td>
</tr>
<tr>
<td>permanent neurologic injury</td>
<td></td>
</tr>
<tr>
<td>cerebral circulation vulnerability</td>
<td>763</td>
</tr>
<tr>
<td>cerebral palsy</td>
<td>762</td>
</tr>
<tr>
<td>clinical indicators</td>
<td>762–763</td>
</tr>
<tr>
<td>EFM, role of</td>
<td>763–765</td>
</tr>
<tr>
<td>etiology</td>
<td>761</td>
</tr>
<tr>
<td>hypoxic ischemic encephalopathy</td>
<td>762</td>
</tr>
<tr>
<td>incidence of</td>
<td>762</td>
</tr>
<tr>
<td>mental retardation</td>
<td>762</td>
</tr>
<tr>
<td>neonatal encephalopathy</td>
<td>761–762</td>
</tr>
<tr>
<td>pathology</td>
<td>763</td>
</tr>
<tr>
<td>terminology</td>
<td>761</td>
</tr>
<tr>
<td>treatment/therapies</td>
<td>763</td>
</tr>
<tr>
<td>retinal hemorrhage</td>
<td>754–755</td>
</tr>
<tr>
<td>scalp injuries</td>
<td>743–745</td>
</tr>
<tr>
<td>shoulder dystocia</td>
<td></td>
</tr>
<tr>
<td>See also macrosomia/shoulder dystocia terms</td>
<td></td>
</tr>
<tr>
<td>See also shoulder dystocia              terims</td>
<td></td>
</tr>
<tr>
<td>brachial plexus injuries</td>
<td>756</td>
</tr>
<tr>
<td>cesarean delivery</td>
<td></td>
</tr>
<tr>
<td>clinical observations of</td>
<td>755</td>
</tr>
<tr>
<td>fetalmacrosomia</td>
<td>757</td>
</tr>
<tr>
<td>fetopelvic relationship</td>
<td>758</td>
</tr>
<tr>
<td>incidence of</td>
<td>755</td>
</tr>
<tr>
<td>morbidity/mortality</td>
<td>755–756</td>
</tr>
<tr>
<td>prediction of</td>
<td>757</td>
</tr>
<tr>
<td>pseudo-Erb palsy</td>
<td>756</td>
</tr>
<tr>
<td>recovery</td>
<td>756–757</td>
</tr>
<tr>
<td>treatment/management</td>
<td>756, 757</td>
</tr>
<tr>
<td>Weigart palsy</td>
<td>350, 756</td>
</tr>
<tr>
<td>skull/facial fractures</td>
<td></td>
</tr>
<tr>
<td>cranial plasticity</td>
<td>748</td>
</tr>
<tr>
<td>dental defects</td>
<td>749</td>
</tr>
<tr>
<td>depressed fractures</td>
<td>748</td>
</tr>
<tr>
<td>diagnosis</td>
<td>748–749</td>
</tr>
<tr>
<td>identification of</td>
<td>748</td>
</tr>
<tr>
<td>leptomeningeal cysts</td>
<td>749</td>
</tr>
<tr>
<td>nasal injuries</td>
<td>749</td>
</tr>
<tr>
<td>occipital osteodistasis</td>
<td>749</td>
</tr>
<tr>
<td>treatment/management</td>
<td>749</td>
</tr>
<tr>
<td>spinal cord injuries</td>
<td></td>
</tr>
<tr>
<td>cranial hyperextension</td>
<td>752</td>
</tr>
<tr>
<td>diagnosis</td>
<td>751</td>
</tr>
<tr>
<td>experimental/simulation findings</td>
<td>752</td>
</tr>
<tr>
<td>incidence of</td>
<td>751–752</td>
</tr>
<tr>
<td>treatment</td>
<td>752–753</td>
</tr>
<tr>
<td>subgaleal/subaponeurotic hemorrhage</td>
<td></td>
</tr>
<tr>
<td>diagnosis</td>
<td>747</td>
</tr>
<tr>
<td>incidence of</td>
<td>747</td>
</tr>
<tr>
<td>morbidity/mortality</td>
<td>748</td>
</tr>
<tr>
<td>pathlogy</td>
<td>746–747</td>
</tr>
<tr>
<td>prevention of</td>
<td>747</td>
</tr>
<tr>
<td>treatment</td>
<td>747–748</td>
</tr>
<tr>
<td>visceral injuries</td>
<td></td>
</tr>
<tr>
<td>in instrumental delivery</td>
<td>754</td>
</tr>
<tr>
<td>intra-abdominal organs</td>
<td>758</td>
</tr>
<tr>
<td>subcutaneous fat neurosis</td>
<td>758</td>
</tr>
<tr>
<td>birth injuries</td>
<td></td>
</tr>
<tr>
<td>in clinical settings</td>
<td></td>
</tr>
<tr>
<td>cesarean delivery</td>
<td>727</td>
</tr>
<tr>
<td>See also cesarean delivery terms</td>
<td></td>
</tr>
<tr>
<td>dystocia/macrosomia</td>
<td>727–728</td>
</tr>
<tr>
<td>See also macrosomia/shoulder dystocia terms</td>
<td></td>
</tr>
<tr>
<td>fetal monitoring</td>
<td>729–730</td>
</tr>
<tr>
<td>See also fetal monitoring terms</td>
<td></td>
</tr>
<tr>
<td>instrumental delivery</td>
<td>728–729</td>
</tr>
<tr>
<td>See also instrumental delivery terms</td>
<td></td>
</tr>
<tr>
<td>overview</td>
<td>725–726</td>
</tr>
<tr>
<td>birth injuries, maternal</td>
<td></td>
</tr>
<tr>
<td>See also episiotomy/extensions</td>
<td></td>
</tr>
<tr>
<td>amniotic fluid embolism (AFE).</td>
<td></td>
</tr>
<tr>
<td>causes of death</td>
<td>737</td>
</tr>
<tr>
<td>clinical symptoms, acute</td>
<td>737–738</td>
</tr>
<tr>
<td>diagnosis</td>
<td>738–739</td>
</tr>
<tr>
<td>etiology</td>
<td>736</td>
</tr>
<tr>
<td>incidence of</td>
<td>736–737</td>
</tr>
<tr>
<td>morbidity/mortality</td>
<td>736, 738</td>
</tr>
<tr>
<td>pathophysiology</td>
<td>736</td>
</tr>
<tr>
<td>treatment</td>
<td>738, 739</td>
</tr>
<tr>
<td>coccyx</td>
<td></td>
</tr>
<tr>
<td>coccyx anatomy</td>
<td>741</td>
</tr>
<tr>
<td>diagnosis</td>
<td>741–742</td>
</tr>
<tr>
<td>etiology/symptoms</td>
<td>741</td>
</tr>
<tr>
<td>treatment</td>
<td>742</td>
</tr>
<tr>
<td>infection</td>
<td>733</td>
</tr>
<tr>
<td>medical errors</td>
<td></td>
</tr>
<tr>
<td>crew resource management</td>
<td>743</td>
</tr>
<tr>
<td>medication errors</td>
<td>743</td>
</tr>
<tr>
<td>patient/surgical site identification</td>
<td>742–743</td>
</tr>
<tr>
<td>study findings</td>
<td>742</td>
</tr>
<tr>
<td>pelvic relaxation syndrome</td>
<td></td>
</tr>
<tr>
<td>anatomy of</td>
<td>739–740</td>
</tr>
<tr>
<td>chronic pelvic joint pain</td>
<td>740</td>
</tr>
<tr>
<td>diagnosis</td>
<td>740</td>
</tr>
<tr>
<td>etiology</td>
<td>739</td>
</tr>
<tr>
<td>osteomyelitis</td>
<td>741</td>
</tr>
<tr>
<td>symphysis rupture/division</td>
<td>740–741</td>
</tr>
<tr>
<td>symptoms</td>
<td>740</td>
</tr>
<tr>
<td>treatment</td>
<td>740</td>
</tr>
<tr>
<td>urinary tract infection (UTI)</td>
<td>733–734</td>
</tr>
<tr>
<td>uterine atony/inversion</td>
<td>735–736</td>
</tr>
<tr>
<td>See also uterine atony/inverson</td>
<td></td>
</tr>
<tr>
<td>uterine atony</td>
<td>734</td>
</tr>
<tr>
<td>uterine inversion</td>
<td>734</td>
</tr>
<tr>
<td>vaginal/cervical lacerations</td>
<td>732–735</td>
</tr>
</tbody>
</table>
bladder injury/management

bladder injuries, 622
bladder repair, 622–623
vesicocervical/vesicouterine fistula repair, 624
vesicovaginal fistula repair, 623–624

BPP. See biophysical profile (BPP).

Brace suture (B-Lynch suture), 278

brachial plexus

anatomy of, 350
injury classifications
Erb’s palsy, 350
Horner’s syndrome, 350
Klumpke palsy, 350
Weigart palsy, 350, 756
injury occurrence, 350–351, 355–356
brachial plexus injuries, 314–315. See also shoulder impaction.
brachial plexus palsy, 349–351, 356–357. See also shoulder dystocia terms; shoulder impaction.
Bracht maneuver, 303. See also breech presentation, delivery techniques.
Brandt-Andrews maneuver, 218, 260–261
breech presentation

adverse outcomes, 297
cesarean indications, 297–299
cesarean vs. vaginal delivery, 317
definitions/types of, 300
fetal/maternal risk balance, 299
incidence of, 297
labor, mechanisms of, 300–301
low-birth weight fetasus, 299
operative delivery rate, 299
patient counseling, 316–317
residency education, 317
risk factors, 297, 298
trial of labor, 299–300
vaginal delivery, pre-modern, 297

breech presentation, delivery techniques

aftercoming head delivery
Kristellar maneuver, 303
Mauriceau-Smellie-Viet (MSV) maneuver, 303
Naujok’s maneuver, 303
Prague maneuver, 303–304
Wigand-Martin-Winkle maneuver, 303

approaches, type of, 301
assisted breech delivery
Bracht maneuver, 303
fetal position, 301
Loveset maneuver, 301–303

breech extraction

partial breech extraction, 304–305
total breech extraction, 304
cesarean delivery, 306
external cephalic version, 307, 312–313
forceps in, 305
internal podalic version, 306–307
selective trial of labor, 308
spontaneous breech delivery, 305–306

breech presentation, labor and delivery management

anesthesia support, 313
cesarean delivery, elective, 312
current practice, 313–314
delivery room equipment, 313
pediatric support, 313
personnel requirements, 313
trial of labor (TOL)
dilation/descent, 309–310
fetal acidosis, 309
fetal outcome, 312
imminent delivery, 310–311
low-birthweight fetus, 312
maternal evaluation, 309
progression of labor, 309
umbilicus appearance, 312
vaginal delivery, 311–312

breech presentation, outcomes

preterm infants
cesarean vs. vaginal delivery, 316
delivery risk factors, 315
external cephalic version, 315–316
VLBW/low-birthweight infants, 316
term infants
bone injury/nerve damage, 315
brachial plexus injuries, 314–315
cerebral palsy, 314
cesarean delivery, 315
congenital abnormalities, 314
ECV-related injuries, 315
resuscitation at delivery, 315
traumatic injury, 314
worldwide study results, 315
bupivacaine, 195, 198
fentanyl combination therapy, 204
in postoperative pain management, 218
butorphanol, 196, 212

Caesar, Gaius Julius, 3
castration, accidental, 754
CCAMs (congenital cystic adenomatotic malformations), 648–650
CDH. See congenital diaphragmatic hernia (CDH).
cerebral atresia, 450–451
chophalohematoma, 745–746
cerebral palsy, 314
congenital diaphragmatic hernia (CDH), 245, 246, 463–464
cerebral palsy; cervical insufficiency; cervicothoracic cerclage (TACIC).
cerebral palsy (CP), 314, 323–324, 762
cervical cerclage. See also cervical insufficiency; cervicothoracic cerclage (TACIC).
efficacy of, 92–93
epidemiology, 92–93
cervical incompetence. See cervical insufficiency.
cervical insufficiency
acquired cervical lesions
conization, 91
lacerations, 91
cerclage operations
incidence of, 92
indications, 111
intraoperative complications, 95–96
intrauterine infections, 95–96, 102
membrane rupture, 96, 102–103
postoperative complications, 95, 96
postoperative treatment, 96–97
surgical technique, 108–111
congenital factors, 91
diagnosis
obstetric history, 93
sonography, 94–95
techniques for, 93–94
epidemiology, 92
historical observations/procedures, 90
nonsurgical treatment, 111
pathophysiology, 90–91
pessary insertion, 111
preterm delivery risk, 89–90
sonography
endovaginal, 94
significance of, 94–95
transperineal/transvaginal, 94
Valsalva maneuver, 94
surgical procedures
cervicoisthmic cerclage (TACIC), 104–107
classifications of, 97
elective cerclage, 97, 99
emergency cerclage, 98–99, 100–101
McDonald cerclage, 101–102, 103–104
Shirodkar cerclage, 101–102, 103
and tocolytic therapy, 102
trendelenburg’s positioning, 102
urgent cerclage, 97
transcervical cerclage
Lash operation, 107
Mann cerclage, 107
Page “wrapping” technique, 107
trachelorrhaphy, 107
Wurm technique, 107–108
cervical intraepithelial neoplasia (CIN)
biopsy, 425
colposcopy, 424–425
cytology, 424
risk factors, 424
treatment, 425
cervical length assessment. See ultrasound, cervical length assessment.
cervical malignancy
classification/staging, 426–427
diagnosis, 425–426
epidemiology, 425
management, 427–428
pathology, 426
prognosis, 428
cervical pregnancy, 83
cervicoisthmic cerclage (TACIC)
laparoscopic approach, 107
transabdominal approach, 105–107
transvaginal approach, 107
cesarean delivery
delivery rate
international comparisons, 510–511
vaginal delivery effects on, 512–513
documentation, 564
epidural anesthesia. See obstetric anesthesia.
morbidity reduction, 567–568
cesarean delivery, and VBAC trial
epidural analgesia/anesthesia, use of, 537
fetal macrosomia, 537
issues of concern, summarized, 533
management, 537
morbidity/mortality, 533
multiple prior cesareans, 536–537
twins and breech position, 537
uterine exploration, 536
uterine scar separation
clinical consequence, 535
clinical risk, 535
dehiscence vs. rupture, 533–534
literature review/data interpretation, 534
maternal morbidity, 535
oxygen stimulation, 534–535
patient counseling, 535
repeat rupture, 535
uterine rupture, 535–536
cesarean delivery, associated risk factors
breech presentation, 512
demographic factors
maternal age, 512
medicolegal environment, 512
socioeconomic factors, 512
dystocia, 511. See also shoulder dystocia terms.
electronic fetal monitoring, 511–512
repeat procedures, 511
cesarean delivery, complications
fetal injury, 566–567
general/frequent complications, 564
management of, 564–565
wound disruption, 565–566
cesarean delivery, elective procedures
controversy of, 539, 540
indications for, 538–539
morbidity/mortality, 540
obstetrician opinion survey results, 539–540
operative delivery rates, 538, 539
timing of, 537–538
cesarean delivery, fetal indications.
See also thrombocytopenia (TTP).
abnormal presentation, 522
fetal anomalies, 522–523
fetal compromise, suspicion of, 522–523
fetal macrosomia, 530–531
hepatitis C virus (HCV)
chronicity, 529
incidence/seroprevalence, 528–529
cesarean delivery (Contd.)
indicators, 528
interferon/ribavirin therapy, 529–530
obstetric management, 529
perinatal transmission, 529
spontaneous cure rates, 529
types, 528
herpes simplex virus (HSV)
and AIDS/HIV, 525
asymptomatic carriers, 525
diagnosis, 525
fetal infection, 524–525
incidence of, 524
management, 525
STD screening, 525
human immunodeficiency virus (HIV)
antiretroviral therapy, 526–527
management/treatment, 527–528
pathology, 526
perinatal transmission, 527
prevalence, 526
multiple gestation, 530
cesarean delivery, history of, 509
cesarean delivery, maternal indications.
See also thrombocytopenia (TTP).
birth canal obstruction, 517–518
cerebral aneurysm/arteriovenous
malformation, 519
cervical cancer, 518–519
combined indications, 522
connective tissue disorders
Ehlers-Danlos syndrome (EDS), 520–521
Marfan’s syndrome, 519–520
hypertension, 521
informed consent, 522
pelvic malformations, 521
placenta accreta/incipient/percreta, 516
placenta previa, 513–516
vaginal surgery, prior, 519
vasa previa, 517
cesarean delivery, operative procedure.
See also symphysiotomy.
abdominal-pelvic exploration
abdominal wall closure, 558–559
adnexal examination, 557–558
appendix delivery, 558
Camper’s fascia closure, 560
drains/drainage, 558
fascia closure, 559
lavage/irrigation, 558
myometrial wound closure, 558
skin closure, 560
subcutaneous tissue closure, 560
vesicouterine fold closure, 558
additional procedures. See tubal ligation.
alternative technique, 567
anesthesia, 544–545. See also obstetric anesthesia.
auto stapler, 557
cranial delivery difficulty, 553
fetal monitoring, 545–546
general preparation, 545
incision
abdominal wall entry, 547–548
in breech presentation, 551–552
fascia exposure/separation, 548
gutter packing, 549
for morbidly obese patients, 547
myometrial incision, 551
peritoneal incision, 549
rectus muscle division, 548–549
retractors, use of, 549
severed uterine arteries, 553
in transverse lie, 552–553
transverse vs. vertical incisions, 546–547
uterine entry, 549–551
vesicouterine reflection identification, 549
myometrial wound closure, 555–556
peritoneal closure
adhesion formation, 561–562, 563–564
adhesion prevention, 562
closure/nonclosure debate, 560–561, 564
patient outcomes, 563
physiology, 561–562
study findings/limitations, 562–563, 564
placental delivery, 555
skin preparation, 546
uterine closure, 556–557
cesarean delivery, perimortem
ethical issues, 544
fetal outcome/survival, 541
gestational age assessment, 542–543
history of, 541
legal issues, 544
maternal resuscitation, 541, 543
surgical procedures, 543–544
cesarean hysterectomy. See also hemorrhage, operations for.
history of, 9–10
indications, 568–569
procedure
cervix removal, 570, 571
closure, 571–572
complications, 572
hemorrhage control, 569, 570–571
hysterectomy technique, 569–570
incision, 569
cesarean, term derivation
Caesar myth, 3
current usage, 4
Latin roots, 3
from legal responses, 3
in medical literature, 3
“section” linkage, 3–4
Chamberlen forceps, 12–14, 15
chloroprocaine, 198
choriocarcinoma, 439. See also gestational trophoblastic
disease; ovarian tumors
chorionic villus sampling (CVS)
vs. amniocentesis, 30–31, 32–33
complications
general, 31
limb anomalies, 31, 32
oromandibular-limb hypogenesis, 32
transverse limb reduction defects (TLRD), 32
contraindications, 30
efficacy of, 30
gestational restrictions to, 30
laboratory problems, 35–36
maternal cell contamination (MCC), 30–31
mosaicism, 30–31
specimen assessment, 30
study design/evaluation, 31
transabdominal biopsy (TA-CVS)
single-needle technique, 30
two-needle technique, 29–30
transcervical biopsy (TC-CVS)
procedure, 29
ultrasonic assessment, 29
chromosomal aneuploidy, 33–34
cimetidine, 195, 200
CIN. See cervical intraepithelial neoplasia (CIN).
clinical pelvimetry
as controversial technique, 241–242
limitations, 242–243
measurement techniques, 242
use/utility of, 242, 243
clonidine, 196
cogulopathy, in neuraxial procedures, 211
cocaine, 200–201. . See also illicit drugs/alcohol
coccygodynia
coccyx anatomy, 741
diagnosis, 741–742
etiology/symptoms, 741
treatment, 742
combined spinal/epidural (CSE) analgesia
duration, 214
vs. epidural anesthesia, 214
vs. general anesthesia, 214
in labor pain management, 210–211
sequential CSE, 214–215
computed tomography (CT) scan, in labor, 243
genital cystic adenomatotic malformations (CCAMs), 648–650
genital diaphragmatic hernia (CDH)
clinical outcomes, 652–653
EXIT-to-ECMO intervention, 653
morbidity/mortality, 652
open diaphragmatic repair, 652
tracheal occlusion, 652, 653
continuous quality improvement (CQI), 220–221
Coombs’ test, 28
corticosteroids, antenatal, 337
couvelaire uterus, 170
CP (cerebral palsy), 314, 323–324, 762
CPD (cephalopelvic disproportion), 245, 246, 463–464
cranial deflection correction, 485–486
Credé method, 261
CSE. See combined spinal/epidural (CSE analgesia).
CVS. See chorionic villus sampling (CVS).
death. See perinatal loss.
deep vein thrombosis (DVT). See under surgery in pregnancy, systemic complications.
DeLee, Joseph Bolivar, 17–18
DES (diethylstilbestrol), 91
desflurane, 197
diazepam, 195
dichorionic-diamniotic placenta, 325. . See also multiple gestation, physiology of.
diethylstilbestrol (DES), 91
Doppler, Christian, 51. . See also ultrasound, Doppler.
DVT (deep vein thrombosis). See under surgery in pregnancy, systemic complications.
dysgerminoma, 438–439. . See also ovarian tumors.
eclampsia. See preeclampsia/eclampsia.
ectopic pregnancy
diagnosis

differential, 76
empiric treatment, 77
hormonal assays, 74–75
surgical, 76–77
symptoms, 74
epidemiology, 69–70
future detection/management directions, 84
future fertility, 78–80
maternal mortality, 70
vs. normal pregnancy, 69
pathophysiology
extrauterine, 73
tubal, 70–71
Rh prophylaxis, 83–84
risk factors
age, 73
contraception, 72
ectopic pregnancy, prior, 72, 77
infertility/infertility treatment, 73, 77
maternal DES exposure, 73
pelvic inflammatory disease (PID), 71–72
smoking, 73
surgical sterilization, 72
tubal surgery, prior, 72–73
surgical diagnosis
approaches, 76
frozen section analysis, 76
laparoscopy, 77
pipelle biopsy, 76–77
surgical management
prophylactic methotrexate, 78
salpingectomy, 78
salpingostomy, 77–78
transvaginal ultrasound
B-hCG levels, 75, 76
ectopic pregnancy (Contd.)

diagnostic accuracy, 75–76
gestational sac observation, 75
vs. transabdominal approach, 75

treatment
abdominal pregnancy, 81
cervical pregnancy, 83
expectant management, 81
heterotopic pregnancy, 81
interstitial (cornual) pregnancy, 83
medical management, 80–81
ovarian pregnancy, 81
surgical management, 77–80

uncommon types
abdominal, 81
cervical, 83
heterotopic, 81
interstitial (cornual), 83
ovarian, 81

ECV. See external cephalic version (ECV).
education/certification. See medical simulations.

EFM (electronic fetal heart rate monitoring), 683–684. See also fetal monitoring terms.

Ehlers-Danlos syndrome (EDS), 520–521
Elliot, George T., 17
embryonal carcinomas, 439. See also ovarian tumors.

Emergency Medical Treatment and Labor Act (EMTALA) rules. See under legal principles.

endoanal examination, 62
endodermal sinus tumors, 439. See also ovarian tumors.
endometrial carcinoma
epidemiology, 431
management, 431–432
pathology, 431
prognosis, 432
endometriosis, 734
enflurane, 197, 200
epidural analgesic technique.
See also labor pain management; obstetric anesthesia.
catheter dislodgment/malposition, 206
catheter placement, 205
delivery management, 207–208
dosing
loading, 205
maintenance, 205–206, 207
subdural erosion, 206
subdural injection, 205–206
epinephrine, 198, 201, 204
episiotomy/extensisons
adverse effects, 731
complications, long-term, 731
elective perineal incision, 731
historic advocacy/acceptance, 269–270
injury reduction claims, 730
injury risks, 730
lacerations, occurrence of, 270
perineal lacerations, 271
rectal dysfunction/incontinence issues,
repair techniques, 730–731
supporting studies/claims, 270–272
timing of, 271
episiotomy repair, 265, 266–268. See also perineal/perirethral injuries.
epithelial cell tumors, 438. See also ovarian tumors.
Erb's palsy, 350
ergometrine, 263–264
ergot derivatives, 264

ethical issues
fetal viability, 811
general agreements/maxims, 810–811, 817–818
legalistic solutions, avoidance of, 817
physician–patient relationship, 814, 817
prenatal testing, 814. See also prenatal genetic testing.
social/racial inequality, 811

ethical issues, elective termination
characteristic selection, 813–814
congenital abnormalities in, 811–813
maternal/fetal interests, 813

ethical issues, second/third trimesters
ethical parallels, 817
fetal status, uncertainty of, 816–817
informed consent, 816
physician obligations
in detrimental maternal behavior, 815–816
in experimental procedures, 815
in maternal/fetal conflict, 814–815
risk assessment, 814

etomidate, 197
EXIT (ex utero intrapartum treatment) procedure, 646–648, 653
external cephalic version (ECV), 299–300, 307, 312–313. See also breech presentation.

facial nerve palsy, 753–754
failure to progress (FTP), 245
fallopian tube disease
diagnosis, 440
incidence, 440
management, 440–441
pathology, 440
staging, 440
fentanyl
bupivacaine combination therapy, 204
for hypoxia/apnea, 195
in postoperative pain management, 218
in systemic analgesia, 195, 212
fetal birth injuries. See birth injuries, fetal.
fetal fibronectin (FFN) test, 249
fetal monitoring
electronic fetal heart rate monitoring (EFM), 683–684
intrapartum surveillance techniques, 683
pulse oximetry, 713
standard maneuvers, 713–714
fetal monitoring, deceleration recovery
baseline rate/variability, return to, 701
contraction frequency control, 702
deceleration severity classification, 701
EFM tracing, reading of, 701–702
fetal distress
agonal pattern, 702–703
pattern of injury, 702
fetal monitoring, heart rate patterns
fetal deterioration from hypoxia
late decelerations, 697–699
pattern of decelerations, 693–697
recurrent decelerations, 701
variable/prolonged decelerations, 699–701
fetal deterioration without hypoxia, 692–693
fetal well-being estimation, 693–697
long-term neurologic outcome, 709–710
neuroradiological studies, 710
fetal monitoring, intervention timing
pattern assessment, 715
pattern progression, 714
prevention vs. rescue role, 714–715
fetal monitoring, neurologic injury diagnosis
FHR patterns, use of, 710
hypoxic/ischemic episode, 711–713
injury severity, 710–711
fetal monitoring, physiological principles
baseline heart rate, 687
FHR pattern influences, 686
tachycardia/bradycardia
basal vs. baseline rates, 687
baseline variability measurement, 689
contributing factors, 687
development speed of, 687–688
diagnosis, 690
irregular fluctuations, 688–689
saltatory/jumping patterns, 690–691
servocontrol mechanisms, 689
variability, causes of, 689–690
fetal monitoring, second stage of labor complications/risks, 705
decelerations, frequency of, 703
excessive uterine activity, 704–705
fetal blood sampling
technique, 708–709
tissue pH maintenance, 708
maternal pushing strategies, 703–704
nomenclature issues, 703–706
tracing abnormalities, 706–708
fetal monitoring, surveillance methods
vs. adult coronary care systems, 686
contraction effects
fetal stimulation, 686
on uterine blood flow (UBF), 685–686
EFM functions
heart rate measurements, 685
uterine contraction measurements, 685
intermittent auscultations (IA), 684–685
fetal occiput position
digital examination for, 57–58
identifying landmarks, 58
as labor management tool, 56–57
malposition/malrotation, 58
transvaginal examination, 58
fetal position assessment. See ultrasound, fetal position assessment.
fetal status assessment. See ultrasound, fetal status assessment
fetal surgery
fetal ethics.
See also ethical issues terms.
  informed consent, 639–640
  maternal-fetal conflicts, 638–639
  maternal safety, 639, 640
  preoperative diagnosis, 640–641
fetal surgery, established applications
airway obstruction
causes/diagnosis, 646
EXIT procedure, 646–648
bladder outlet obstruction
diagnosis, 651
indications, 651–652
procedures, 652
sacrococcygeal teratomas (SCT), 650–651
thoracic anomalies
congenital cystic adenomatotic malformations (CCAMs), 648–650
hydrothoraces, 648
twin-reversed arterial perfusion (TRAP) sequence, 646
twin-twin transfusion syndrome (TTTS)
  alternative interventions, 645–646
  amnioreduction, 645
  fetoscopic laser ablation, 645
  mortality/morbidity, 645
  pathophysiology, 645
fetal surgery, experimental applications. See aortic stenosis;
  congenital diaphragmatic hernia (CDH);
  myelomeningocele (MMC).
fetal surgery, general operative approaches
challenging factors, 641
fetoscopic surgery
  advantages/disadvantages of, 644
  development of, 643
  preoperative preparation, 643
  specialist roles, 643
  surgical procedures, 643
open fetal surgery
  postoperative activity, 642–643
  preoperative preparation, 641
  specialist roles, 641
  surgical procedure, 641–642
  percutaneous approaches, 644–645
fetoscopy, 159
fetus papyraceus, 330–331
FFN (fetal fibronectin) test, 249
fibroids. See leiomyomata.
fibroleiomyomas. See leiomyomata.

fibromyomas. See leiomyomata.

fluorescent in situ hybridization (FISH), 25–37

forceps, historic

axis-traction, 17
Chamberlen, 12–14

destructive vs. atraumatic instruments, 11–12
development/modifications, 11, 15, 18
Elliot's, 17
Palfyn instrument, 14–15
prophylactic forceps operation, 17–18
rotational maneuvers, 17
Simpson's, 17
solid-bladed, 17
term derivation, 11
van Roonhuysian instrument(s), 13–14

Fournier gangrene. See necrotizing fasciitis (NF).

Freud, Sigmund, 821

FTP (failure to progress), 245

Gainey, H. L., 270–271

gallbladder disease. See under surgery in pregnancy, surgical complications.
gas gangrene, 289. See also necrotizing fasciitis (NF).
genetic disease

clinician/obstetrician role, 23
financial/social impacts, 22–23
identification advances, 23
medical importance, 22
genital herpes. See herpes simplex virus (HSV).
germin cell tumors, 438. See also ovarian tumors.
gestational thrombocytopenia (GTP), 532

gestational trophoblastic disease

classification/staging, 418–419
diagnosis, 417–418
epidemiology, 416
historic recognition of, 416
management

follow-up, 422
high-risk metastatic tumors, 421–422
nonmetastatic/low-risk metastatic disease, 419–421
morbidity/mortality, 416–417
pathology, 416–417

gestational trophoblastic neoplasia. See gestational trophoblastic disease.
glycopyrrolate, 195
gonadal stromal tumors, 439–440. See also ovarian tumors.
granulosa cell tumors, 439–440. See also ovarian tumors.
Greenfield filter, 405
grief. See perinatal loss.

GTP (gestational thrombocytopenia), 532. See also thrombocytopenia (TTP).

Guillemeau, Jacques, 4

Haas maneuver, 490
Hale forceps, 471
halothane, 197, 199, 200, 201
Haultain operation, 283

HCV. See hepatitis C virus (HCV).
hemolytic streptococcal gangrene. See necrotizing fasciitis (NF).
hemorrhage. See hemorrhage, operations for; intracranial hemorrhages; massive hemorrhage; postpartum hemorrhage (PPH); subgaleal/subaponeurotic hemorrhage.
hemorrhage, operations for angiographic embolization

advantages/disadvantages of, 581
complications, 581
indications, 580–581
procedure, 581
balloon tamponade, 581–582
hypogastric vessel ligation

complications, 579–580
indications, 579, 580
pelvic circulation effects, 580
problems following, 580
procedure, 579
incidence/risk factors, 572–573
initial management, 572
maternal resuscitation, 573
principal surgical procedures, 573

uterine artery ligation (O'Leary technique)

advantages of, 575
B-Lynch sutures, 576–577
complications, 574–575
compression techniques, 575
drains/drainage, 578
extent of bleeding, judgment of, 577–578
oversewing techniques, 577
packing techniques, 575–576
postoperative management, 578–579
procedure, 573–574

heparin, 402–403, 404–405

hepatitis C virus (HCV)

chronicity, 529
incidence/seroprevalence, 528–529
indications, 528
interferon/ribavirin therapy, 529–530
obstetric management, 529
perinatal transmission, 529
spontaneous cure rates, 529

herpes simplex virus (HSV)

and AIDS/HIV, 525
asymptomatic carriers, 525
diagnosis, 525
fetal infection, 524–525
incidence of, 524
management, 525
STD screening, 525

heterokaryotypia, 332

heterotopic pregnancy, 81

HIE (hypoxic ischemic encephalopathy), 762
high-order multiple gestation (HOM), 340
history. See obstetric history.

HIV. See human immunodeficiency virus (HIV).
HOM (high-order multiple gestation), 340
Horner’s syndrome, 350
hospital gangrene. See necrotizing fasciitis (NF).
HSV. See herpes simplex virus (HSV).
human immunodeficiency virus (HIV) antiretroviral therapy, 526–527
management/treatment, 527–528
pathology, 526
perinatal transmission, 527
prevalence, 526
Huntington procedure, 283
hydatidiform mole. See gestational trophoblastic disease; gestational trophoblastic disease.
hydralazine, 200
hydrostatic uterine replacement, 282
hyperhomocystinemia syndrome (HHCS). See also venous thrombosis (VT).
hypotension treatment, 198
hypoxic ischemic encephalopathy (HIE), 762
hysterectomy. See cesarean hysterectomy.
IA (intermittent auscultations), 684–685
idiopathic thrombocytopenia purpura (ITP). See thrombocytopenia (TTP).
illeocecal cystoplasty bladder augmentation, 629
illicit drugs/alcohol
alcohol abuse complications/therapies, 201
drug interactions
amphetamine, 201
cocaine, 200–201
marijuana, 201
narcotic abuse complications/therapies, 201
indomethacin, 199
infection, 287. See also necrotizing fasciitis (NF); surgery in pregnancy, wound infection.
instrumental delivery
contraindications, 470
equipment, types of
forceps, 459–460
specialized instruments, 461
vacuum extractors, 459–460, 461
follow-up study findings, 499–500
intervention indications
elective shortening of second stage, 457
fetal compromise, suspicion of, 458–459
prolonged second stage, 457
mandatory prerequisites, 456
procedure coding
forceps deliveries, 461–462
vacuum extraction operations, 462 risks. See also instrumental delivery, fetal injuries
from episiotomy, 493–494
in fetal macrosomia, 492
maternal/fetal injuries, 491–492
role of, 442
station system scoring, 456
trial vs. failed procedures, 496–499
instrumental delivery, clinical issues
digital examination errors, 465–466
documentation, 467
pelvic adequacy evaluation
abdominal examination, 464
cephalopelvic disproportion, 463–464
fetal malpositioning, 463
intervention indications, 463
Leopold’s maneuvers, 464
oxytocin stimulation, 465
prolongation/arrest disorders, 463
ultrasound, 464–465
sequential instrument use, 466
training deficiencies, 467–468
instrumental delivery, conduct of
analgesia/anesthesia use, 472
choice of instrument, 477–478
descent, 474
febrile morbidity, 472
forceps application, 474–476
forceps motion, 473
prerequisites, 471–472
traction, 472–473
use of force, 476–477
vacuum extractor, 473–474, 476
instrumental delivery, fetal injuries
from forceps, 494
intracranial hemorrhages, 495
scalp bruising/lacerations, 495
subgaleal/subaponeurotic hemorrhage, 494–495
from vacuum extraction, 494
instrumental delivery, forceps/vacuum extractor comparison
analgesia/anesthesia use, 469
maternal/fetal injuries, 468, 469
in midpelvic procedures, 469
surgeon/practitioner experience level, 468–469
vacuum extractor advantages/application, 469–470
instrumental delivery, instrument application
in breech presentations, 491
fetal station, 482–483
forceps operation procedure, 478–480
manual rotation, 483
in rotation of 45 degrees or less
forceps operation, 481–482
vacuum extractor technique, 481–482
in rotation of 45 degrees or more
forceps rotation, 482
transverse arrest, 482
Barton forceps, 484
blade introduction, 483
Kielland forceps, 483–484
Tucker-McLean forceps, 483
vacuum extraction procedure, 480–481
instrumental delivery, maternal injuries
perineal lacerations, 495
risk factors, 495–496
stress urinary and anal incontinence, 496
instrumental delivery, occiput posterior (OP) positions associated conditions/complications, 486–487
    incidence of, 486
management
    antepartum repositioning, 487
    Haas maneuver, 490
    instrument/procedure selection, 488–489
    Kielland rotation, 490–491
    manual rotation, 487–488
    procedure failure rates, 488
    Puddicombe’s maneuver, 487
    reverse Scanzoni maneuver, 489–490
    Scanzoni rotation, 489
    vaginal vs. cesarean delivery, 488
    morbidity/mortality, 486
    risk factors, 487
instrumental delivery, special applications
    cranial extraction, 470–471
    multiple gestation, 471
    upward extractor procedure, 471
instrumental delivery, special issues
    asynclitism, 486
    cranial deflection correction, 485–486
    wandering, 485
    intermittent auscultations (IA), 684–685
internal podalic version (IPV), 306–307. See also breech presentation, delivery techniques.
interstitial (cornual) pregnancy, 83
intrauterine growth restriction (IUGR), 289, 298, 314
intravenous patient-controlled analgesia (IV-PCA), 212, 218
intrauterine growth restriction (IUGR), 289, 298, 314
intravenous pyelography (IVP) use, 626
invasive mole. See gestational trophoblastic disease.
IPV (internal podalic version), 306–307. See also breech presentation, delivery techniques.
isoflurane, 197
ITP (idiopathic thrombocytopenia purpura). See thrombocytopenia (TPP).
IUGR (intrauterine growth restriction), 289, 298, 314
IV-PCA (intravenous patient-controlled analgesia), 212, 218
IVP (intravenous pyelography) use, 626
Jonas, Richard, 3, 4
ketamine, 196–197, 199, 201
ketorolac, 196, 201
Kielland forceps, 305
    Kielland rotation, 490–491
    Kleihauer-Betke test, 155
    Klumpke palsy, 350
    Kristellar maneuver, 303. See also breech presentation, delivery techniques.
    Kühler-Ross, Elisabeth, 821
    Kustner procedure, 283
    labetalol, 200, 201
    labor, abnormal conduct
dystocia
    causes, 245
    disproportion, 245–246
    “pelvic/passenger/powers” issues, 245
    malpresentation/disproportion diagnosis CPD, 246
    cranial molding estimation, 246–247
    etiology establishment, 246
    Müller-Hillis maneuver, 246
    oxytocin stimulation, 246
    palpation techniques, 246
    ultrasound, real time, 247
    management of latent phase treatment, 247
    oxytocin stimulation/augmentation, 247–248
    labor, active management of American/Canadian experience, 252
    Dublin group system, 252
    labor induction/augmentation
    contraindications/criteria, 249
    fetal fibronectin (FFN) test, 249
    indications, 248–249
    mechanical methods
    amniotomy, 250
    cervical dilators, 250
    cervical ripening, 249
    Foley catheter, 250
    membrane sweeping, 249–250
    oxytocin, 251–252
    pelvic examination, 249
    prostaglandins, 250–251
    timing of, 252
    labor, normal conduct, 252. See also labor pain management; labor pain management, epidural blockade; obstetric anesthesia.
    analgesia, 234
    clinical pelvimetry
    as controversial technique, 241–242
    limitations, 242–243
    measurement techniques, 242
    use/utility of, 242, 243
    clinician/obstetrician role, 232
    computed tomography (CT) scan, 243
    cranial flexion evaluation, 244
    diagnosis of labor, 233–234
    epidural anesthesia, 244–245
    fetal position/presentation, 240
fetopelvic relationship
  fetal size estimation, 241
  pelvic types/architecture, 240–241
  maternal posture effects, 239–240
  medical/surgical intervention, 240
  patient history/examination, 232–233
  physiology of, 248
  premature rupture of membranes (PROM), 233
  radiographic (x-ray) pelvimetry, 243
  ultrasound, real-time, 243–244
labor pain
  characteristics of, 202
  complications from, 202
  natural childbirth beliefs, 202
  patient expectations, 202
  prenatal childbirth training (PCT) effectiveness, 202
labor pain management. See also obstetric anesthesia
  combined spinal/epidural (CSE) analgesia, 210–211
  paracervical block (PCB), 212
  parturient-controlled epidural analgesia (PCEA), 209
  pudendal block/perineal infiltration, 212–213
  spinal analgesia, 209–210
  systemic analgesia, 211–212
labor pain management, epidural blockade.
  See also epidural analgesic technique.
  analgesic regimen
    vs. anesthesia, 202–203
    delivery management, 207–208
    initiation, 205–206
    maintenance, 206–207
    neuropharmacology of pain, 204
    technique, 204–205
    timing of, 208–209
  contraindications to neuraxial procedures, 211
  hazards, anesthesia-related
    aortocaval compression, 207
    oral intake, 207
  local anesthetics, negative effects, 203–204
  maternal benefits, 206–207
  in second-stage management, 209
  terminology usage, 202
labor, progress of
  evaluation methods, 252
  influencing factors, 252
  intervention judgment, 253
  oxytocin stimulation, 252–253
labor, stages of
  partogram, 237–238
  prolonged labor
    and epidural anesthesia, 239
    fetal monitoring, 238–239
    medical/surgical intervention, 239
    protocol development, 238
    two-hour rule, 238, 239
  ultrasound examination, 238
  station
    cervical dilation, 236
    labor pattern analysis, 236–237
    reporting systems, 234–236
terminology, 234
uterine activity measurement
  manual palpation, 239
  Montevideo units, 239
tocodynamometry, 239
labor, third/fourth stage
  active management
    basic components of, 263
    cord blood drainage/collection, 265
    cord clamping, 264–265
    ergot derivatives, 264
    oxytocin, 263–264
    prostaglandins, 264
    study findings, 263
  uterotonics agents, 263–264.
  complications. See postpartum hemorrhage; uterine inversion.
history
  Bard, John, 258
  Baudeloque, Jean Louis, 258
  British monarchy, 258–259
  Dewees, William P., 258
  Mauriceau, Francois, 257–258
  Smellie, William, 258
  Taj Mahal, 258
  normal physiology
    placental separation, 259
    uterine involution, 259–260
  placenta delivery
    Brandt-Andrews maneuver, 260–261
    cord traction/tension, 260–261
    Credi method, 261
    oxytocin, 263–264
    prostaglandins, 264
    study findings, 263
    separation confirmation, 260
    twisting/lifting methods, 261
    post-delivery placenta examination
      drainage/injection practices, 263
      gross examination, 262–263
lacerations, birth canal
  cervical, 286
  uterine, 286
  vaginal, 286–287
  Lash operation, 107. See also cervical cerclage.
legal considerations, antepartum
  cervical insufficiency
diagnosis/evaluation of, 189–190
  primary considerations, 190–191
  ectopic pregnancy
    communication errors, 181–182
    medicolegal issues, 180
    misdiagnosis, risk of, 181
    primary considerations, 182–183
  genetic testing
    Howard v. Lecher, 179
legal considerations (Contd.)

physician liability theories, 177–178

primary considerations, 179–180

Schirmer v. Mt. Auburn Obstetrics and Gynecologic Assoc., 177–178

standard of care/causation, 179

legal/ethical landscape, 176–177

placental abnormalities, 189

therapeutic abortion

informed consent, 187–188

Martinez v. Long Island Jewish Hillside Medical Center, 187–188

patient rights, 186

Perez v. Park Madison Professional Laboratories, Inc., 187–188

primary considerations, 188

Sheppard-Mobley v. King, 187

wrongful pregnancy, 186–187

ultrasound

personnel expertise, 183–185

primary considerations, 185–186

standard of care issues, 185

legal considerations, birth injuries

causation, 831–832, 851–852

education/training, 837–838

electronic fetal monitoring

Baglio v. St. John’s Queens Hospital, 833–834

in clinical decision making, 833

errors in judgment vs. malpractice, 834

in intrapartum assessment, 833

medical record review/analysis, 834

morbidity/mortality, 383

obstetrician considerations, 834–835

genetic science/counseling, 832, genetic testing. See under legal considerations, antepartum.

indemnity payouts, 831

intrauterine assessment, 832

neurological assessments/abnormalities, 832–833

nurse midwives.

See also midwives/midwifery.

“direct entry” midwives, 838

history, in United States, 838

independent vs. collaborative practice, 839

vs. physician outcomes, 838–839

practitioner considerations, 839–840

regulation of, 838

placental pathology

expert opinions, battle of, 836–837

explanation of neonatal outcomes, 835–836

plaintiff’s burden, 832

legal considerations, fetal surgery


efficacy of, 678

experimental vs. standard medical therapy, 678–679

indications for, 678

informed consent, 679

obstetrician considerations, 680

legal considerations, intra- and postpartum

breech presentation

cesarean indications, 383

complications, 383–384

Draper v. Jasionowski, 384–385

informed consent, 384

obstetrician considerations, 385–386

safe conduct of breech delivery, 384

vaginal delivery, 384–385

cesarean delivery

cesarean on demand controversy, 672, 673

Meador v. Stahler and Gheridian, 674

Schreiber v. Physicians Insurance, 672

damages/jury awards

economic/non-economic, 370–371

Gourley v. Nebraska Methodist Health System, 371

insurer payments, 372

Waring v. United States, 371–372

instrumental delivery

fetal/maternal injury, 372

midforceps operation controversy, 372

obstetrician considerations, 373

malpractice claim reduction, 373

multiple gestation

congenital abnormalities, 387

diagnosis failure, 386

gestational age assessment, 386

Mundell v. La Pata, 386–387

obstetrician considerations, 387–388

tocolytic agents, 387

vaginal vs. operative delivery, 387

obstetric anesthesia

acts or omission, 374

Denton v. LaCroix, 374–375

Lanzet v. Greenberg, 374

maternal mortality, 373

nonmortal injuries, 373–374

Oberzan v. Smith, 374

obstetrician/anesthesiologist responsibility, 374

obstetrician considerations, 375–376

policy/protocol standardization, 374

shoulder dystocia

litigation rebuttal, 389–390

management controversy, 388

obstetrician considerations, 390–391

res ipsa doctrine, 389

tort reform, 370, 372

legal considerations, maternal-fetal conflict

contradictory outcomes

criminal prosecution, 666

Ferguson v. City of Charleston, 666

illicit drug use, 666

fetal-rights advocacy

Jefferson v. Griffin Spalding County Hospital, 664–665
Pemberton v. Tallahassee Memorial Regional Hospital, 665
Planned Parenthood v. Casey, 664
informed consent, 666–667
maternal behaviors, 663–664
maternal-rights advocacy
Matter of Angela C., 665
McFall v. Shrimp, 664
religious convictions, 665–666
Roe v. Wade, 664

legal considerations, surgery in pregnancy
clinical evaluation difficulties, 667–668
common nonobstetric procedures, 667
complications/liability relationship, 668
incidence of, 667
nondelegable duties, 668–669
obstetrician considerations, 669
risk assessment, 668

legal considerations, surgical complications
improper surgical recommendation, 441
improper treatment of complications, 442
surgical technique, 441–442

legal considerations, third stage of labor
Gabaldoni v. Board of Physicians, 672–677
maternal care, 669–672
obstetrician considerations, 680
placental examination, 669
postpartum complications, 677–680
postpartum hemorrhage (PPH), 680

legal considerations, urologic complications
delayed diagnosis risks, 677
maternal/fetal injuries, 675–676
negligence allegations, 676
principles for practice, 677–678
 Seats v. Lowery, 676–677

legal principles
abortion, legal decisions in
Harris v. McRae, 867
Maher v. Roe, 867
Planned Parenthood v. Casey, 867–868
Roe v. Wade, 866–867
Stenberg v. Carhart, 868

authoritative sources/learned treatises
in evidence introduction, 861, 862
Federal rule regarding, 859–860
 Gridley v. Johnson, 860
 Jacober v. St. Peters Medical Center, 860–861
Kidpatrick v. Wolford, 861–862
 Swank v. Hallivopoulos, 860

cause, 851–852
duty (doctor–patient relationship)
consultation between professionals, 844–845, 846
de minimis contact, 844
Gilinsky v. Indeliciato, 845–846
implied contract, 844
 Wheeler v. Yvette Kersting Memorial Hospital, 845

EMTALA rules
 Burditt v. United States, 864–865
Marshall v. East Carroll Parish Hospital, 862
patient “dumping”, 862
patient transfer, 863–864, 865
 requirement of, 862, 865
screening examination, 862, 863
 Urban v. King, 864
U.S. v. Rush Foundation Hospital, 862–863

expert witness
jury consideration of, 857–858
 Lake v. Clark, 859
qualifications of, 858
Sheely v. Leslie, 858–859

informed consent
Canterbury v. Spence, 855–856
customary practice standard, 855
Dingle v. Belin, 855
Harrison v. United States, 856–857
materiality standard, 856
medical/expert testimony, 857

loss-of-chance doctrine
vs. “all-or-nothing” rule, 852–853
compensable injury, 854
probabilities vs. possibilities, 853–854
as reduced standard of causation, 852
substantial factor test, 854–855

medical malpractice, 843–844
new technology, standard of care, 865–866
physician as Good Samaritan
Good Samaritan legislation, 848–849
 Hurley v. Eddingfield, 848
vs. layperson, 848
reasonable care, 848
 United States v. DeVane, 848
Velazquez vs. Jimenez, 849–850
standard of care issues, 850–851
supervision of resident physicians
Maxwell v. Cole, 846
McCullough v. Hutzel Hospital, 847
 Moeller v. Hauser, 846–847
Mozingo v. Pitt City Memorial Hospital, 847–848
wrongful life/wrongful birth
Becker v. Schwartz, 868–869
 Gallagher v. Duke University Hospital, 870
 genetic technology, 868–870
injury, nature of, 869
physician negligence, 868
Reed v. Campagnolo, 869
Roe v. Wade, 868–869, 870

Siemieniec v. Lutheran General Hospital, 869–870

leiomyobromas. See leiomyomata.
leiomyomata
diagnosis, 430
epidemiology, 429
management, 430
pathology, 429–430
prognosis, 430–431
levobupivacaine, 198
lidocaine, 198, 200
INDEX

Loveset maneuver, 301–303
lower urinary tract injuries and trauma.
See also bladder injury/management; ureteral
injury/management; urethral injury/management.
accidental trauma, 620
intrapartum injuries, 620–621
surgical injuries, 621–622
lumbosacral palsy (LSP), 773–774

macrosomia
diagnosis
fetal weight assessment, 352
ultrasound reliability, 352
lab abnormalities, 353–354
management/injury profile, 361–362
related risks
maternal diabetes, 353
maternal factors, 353
maternal weight, 352
post-term pregnancy, 352
prior macrosomic infant, 352–353
magnesium sulfate, 199
magnetic resonance imaging (MRI), 158–159
Malmström extractor, 18–19
Mann cerclage, 107. See also cervical cerclage
Marfan’s syndrome, 519–520
marijuana, 201
MSAFP (maternal serum alpha fetoprotein), 27
massive hemorrhage, obstetric
anesthetic management, 216–217
causes/treatment, 216
childbirth vs. surgery misperception, 217
maternal cell contamination (MCC), 30–31
maternal-fetal medicine (MFM) specialists, 335–336
maternal serum alpha fetoprotein (MSAFP)
elevation, 27
Mauriceau, François, 5–7, 13, 257–258
Mauriceau-Smellie-Viet (MSV) maneuver, 303, . See also
breech presentation, delivery techniques.
maximum vertical pocket (MVP), 49
MCC (maternal cell contamination), 30–31
McDonald cerclage, 101–102, 103–104. See also
cervical cerclage.
McGill Pain Questionnaire, 202
medical simulations
continuing education, role in, 806
development of, 797–798
example simulations
bad-news communication, 805
circumcision, 804
documentation training, 804–805
eclampsia, 803
operative vaginal delivery, 803, 805–806
postpartum hemorrhage, 802–803
professionalism scenarios, 805
shoulder dystocia, 801–802
surgical skill assessment, 806
ultrasound scanning/procedures, 803–804
vaginal breech delivery, 804
future applications, 808
in graduate medical education, 801
patient safety/outcomes, 806–807
rationale for, 799–800
simulation products, 798–799
team drills, 807–808
as training tool, 798
in undergraduate medical education, 800–801
Meigs, Charles, 193
Melaney’s ulcer, 289. See also necrotizing fasciitis (NF).
membranous twin, 330–331
methamphetamine, 201
methergonovine maleate, 264
methotrexate therapy
contraindications, 80
future fertility, 81
side effects, 80–81
single/multidose therapies, 80
uses of, 80
metoclopramide, 195
MFM (maternal-fetal medicine) specialists, 335–336
midwives/midwifery
circumcision, newborn, 794
core competencies, 789–790
first assisting, 792–793
intervention, role of, 795–796
procedures performed by, 787, 789
technology, appropriate role of, 795
training/credentialing
American College of Nurse-Midwives (ACNM), 788
clinical privileging, 791
liability concerns, 791–792
of physician assistants (PAs), 788–789
state laws/regulations, importance of, 791
trends/future
at-risk evaluation, 794
cesarean delivery rates, 795
hospitalist movement, 794–795
laborists, role of, 794–795
medical education, 795
vacuum-assisted birth, 793–794
mifepristone (RU 486), 133–134
Misgav-Ladach (ML) cesarean technique, 567
misoprostol
in labor induction/augmentation, 250–251
in third/fourth stage labor, 264
mixed germ cell tumors, 439. See also ovarian tumors.
MMC. See myelomeningocele (MMC)
mixedchorionic-diamniotic placenta, 325. See also
multiple gestation, physiology of.
mixedchorionic-monoamniotic placenta, 325. See also
multiple gestation, physiology of.
Montevideo units, 239
morphine, 195, 218
mosaicism, 30–31
MP (meralgia paresthetica), 770–771
MRI (magnetic resonance imaging), 158–159
Müller-Hillis maneuver, 246
Müllerian anomalies, 91
multiple gestation.

See also twin-twin transfusion syndrome.
acardiac twins, 332
antenatal corticosteroids, in triplet gestations, 337
assisted reproductive technology (ART) effects, 322
cerebral palsy, incidence of, 323–324
congenital anomalies, 331–332
diagnosis, 326–327
epidemiology, 322, 324
fetal complications, 329
growth restriction in, 330
high-order multiple gestation (HOM), 340
intrauterine death, 330–331
medicolegal issues, 336–337
monoamniotic twins, 335
perinatal mortality, 322–323
placental/cord complications, 335
preterm birth prevention, 337
preterm labor/delivery
incidence of, 329
predictive factors, 329
psychosocial issues, 341
selective fetocide, 332
selective reduction, 340–341
“vanishing twin” syndrome, 329–330
multiple gestation, antepartum care
maternal–fetal medicine (MFM) specialists, role of, 335–336
prenatal screening, 336–337
prenatal visits/nutrition, 336
ultrasound evaluation, 336
multiple gestation, intrapartum management
interval between deliveries, 338
nonvertex/any presentations, 339–340
vertex/nonvertex presentations, 339
vertex/vertex presentations, 338
multiple gestation, maternal physiologic changes
complications, 328–329
hypertensive disorders, 328
organ system adaptations, 327–328
weight gain, 328
multiple gestation, physiology of
dizygotic twinning, 324
monozygotic twinning, 324–325
placenta
tochorionicity determination, 325–326
complications, 326
dichorionic-diamniotic placenta, 325
monochorionic-diamniotic placenta, 325
monochorionic-monoamniotic placenta, 325
superfetation/superfetation, 324
multiple gestation, preterm labor management
delivery timing, 338
fetal lung maturity, 338
preterm rupture of membranes (PROM), 337
tocolytic therapy, 337
Murless forceps, 471
MVP (maximum vertical pocket), 49
myelomeningocele (MMC)
incidence of, 653
MMC repair approaches, 654
standard of care, 653
study/data interpretation, 654
in utero repair rationale, 653–654
myomas. See leiomyomata.
myonecrosis, 289. See also necrotizing fasciitis (NF).
nalbuphine, 196, 212, 218
naloxone, 201
Naujok’s maneuver, 303. See also breech presentation, delivery techniques.
necrotizing fasciitis (NF)
causative organism, 288
diagnosis, 288
forms/alternate names, 287–288
gas gangrene, 289
laboratory findings, 288
medical management, 289
myonecrosis, 289
surgical treatment, 288–289
symptoms/disease progression, 288
wound infection, 399–400
neoplastic diseases. See cervical intraepithelial neoplasia (CIN); cervical malignancy; endometrial carcinoma; fallopian tube disease; gestational trophoblastic disease; leiomyomata; ovarian tumors; vaginal malignancy; vulvar malignancy.
nestigmine, 196
neuraxial analgesia, 218
neuraxial procedures, contraindications to, 211
NF. See necrotizing fasciitis (NF).
nifedipine, 199
nitroglycerin
in PIH, 200
urgent uterine relaxation, 215–216
in uterine relaxation, 282
nitroprusside, 200
nitrous oxide, 197
obstetric anesthesia.
See also labor pain; labor pain management.
vs. analgesia, 213
drug interactions
illicit drugs, 200–201
obstetric pain management, 201–202
PIH therapy, 200
tocolytic agents, 199
uterotonic agents, 199
epidural anesthesia
obstetric anesthesia (Contd.)
catheter position, 213–214
for cesarean delivery, 213
vs. general anesthesia, 214
pain during, 213
general anesthesia
antacid prophylaxis, 215
practice standards, 215
safety, 215
uses of, 215
for massive hemorrhage, 216–217
pharmacology
analgesics, 195–196
circulation support agents, 197–198
general anesthesia, induction agents, 196–197
general anesthesia, volatile agents, 197
local anesthetics, 198
neuromuscular blocking agents, 198
premedicants, 195
tranquilizers, 195
postoperative pain management, 218
spinal/CSE anesthesia
duration, 214
vs. epidural anesthesia, 214
vs. general anesthesia, 214
sequential CSE, 214–215
surgery during pregnancy
fetal monitoring, 217–218
fetal risks/outcome, 217
general precepts, 217
maternal/fetal survival, 218
vs. surgical anesthesia, 193, 194–195
urgent uterine relaxation, 215–216
obstetric anesthesia service
communication/coordination
characteristics of, 219
informed consent, 220
outpatient anesthesiology clinic, 219–220
management of, 218
quality assurance
continuous quality improvement, 220–221
traditional approaches, 220
staffing/equipment, 218–219
obstetric history. See also forceps, historic.
abortion
in ancient/classical texts, 119
controversy in medical practice, 119
Hippocrates’ injunction, 119–120
legality of, 120
religious doctrines, 120
cesarean delivery
advice against, 5–7
in classic theater, 2
documented operations, 4–5, 7
in myths/legends, 1–2
Porro operation, 9–10
propriety controversy, 5
safety preclusions, 8
self/traumatic delivery, 2
support for, 7
surgical innovations, 9, 10–11
vs. symphysiotomy, 7–8
uterine sutures/suturing, 8–9
cesarean hysterectomy, 9–10
instrumental delivery
advances in, 17
axis-traction forceps, 17
Chamberlen forceps, 12–14
conservative obstetric management, 15
destructive vs. atraumatic instruments, 11–12
Elliot’s midwifery forceps, 17
incidence of procedures, 16–17
instrument development/modifications, 11, 15, 18
intervention error example, 15
maternal mortality, 17
Palfyn instrument, 14–15
popularization of, 15
Princess Charlotte debacle, 15
procedural alternatives, 11
prophylactic forceps operation, 17–18
rotational maneuvers, 17
Simpson’s forceps, 17
solid-bladed forceps, 17
usage guidelines, 15
van Roohuysian instrument(s), 13–14
labor, third/fourth stage
Bard, John, 258
Baudelocque, Jean Louis, 258
British monarchy, 258–259
Dewees, William P., 258
Mauriceau, Francois, 257–258
Smellie, William, 258
Taj Mahal, 258
prenatal genetic testing
amniocentesis, 23–24
chorionic villous biopsy (CVS), 24–25
technologic advances, 25
ultrasonography, 24–25
vacuum extractors
cupping, 18
Malmström extractor, 18–19
Simpson extractor, 18
occiput posterior (OP) positions. See instrumental delivery, occiput posterior (OP) positions.
O’Leary technique, 278, 573–574
oromandibular-limb hypogenesis, 32
ovarian pregnancy, 81
ovarian tumors
classification/staging, 434–435
diagnosis, 433–434
epidemiology, 432
management
benign cystic teratomas, 438
choriocarcinomas, 439
dysgerminoma, 438–439
embryonal carcinomas, 439
© Cambridge University Press
978-0-521-86248-6 - Operative Obstetrics, Second Edition
Edited by John P. O’Grady and Martin L. Gimovsky
Index
More information
Index

endodermal sinus tumors, 439
epithelial cell tumors, 438
germ cell tumors, 438
gonadal stromal tumors, 439–440
granulosa cell tumors, 439–440
mixed germ cell tumors, 439
ovarian cancer, 435–438
ovarian immature teratomas, 439
Sertoli-Leydig cell tumors, 439–440
growth, 432
prognosis, 438
oxytocin stimulation. See also hemorrhage, operations for.
active labor, 263–264
drug interactions, 199
labor, abnormal conduct, 247–248
labor induction/augmentation, 251–252
labor physiology, 248
labor progression, 252–253
malpresentation/disproportion diagnosis, 246
pelvic adequacy evaluation, 465
retained placenta treatment, 284
shoulder dystocia, 354
in third-fourth-stage labor, 263–264
third-fourth-stage labor, 263–264
uterine scar separation, 534–535

Page “wrapping” technique, 107. See also cervical cerclage.
Palfyn instrument, 15
Palfyn, Johannes, 14–15
paracervical block (PCB), 212. See also labor pain management.
Parê, Ambroise, 4, 5–7, 14
parturient-controlled epidural analgesia (PCEA), 209
PAs (physician assistants), 788–789
patient-controlled epidural analgesia (PCA), 212, 218
PCA (patient-controlled analgesia), 218
in hypotension, 199
PCB (paracervical block), 212. See also labor pain management.
PCEA (parturient-controlled epidural analgesia), . See also labor pain management.
PCR (polymerase chain reaction), 25
(PCR) polymerase chain reaction, 36–37
PCT (prenatal childbirth training) effectiveness, 202
pelvic girdle relaxation. See pelvic relaxation syndrome.
pelvic inflammatory disease (PID), 71–72
pelvic relaxation syndrome
anatomy of, 739–740
chronic pelvic joint pain, 740
diagnosis, 740
etiology, 739
osteoarthritis, 741
sympathetic nervous system, 740
symptoms, 740
treatment, 740
percutaneous umbilical blood sampling (PUBS), 60–61
perinatal loss
clinician response to, 821
death, as taboo subject, 820–821
as family trauma, 820
grief, stages of
Freud, Sigmund, 821
Kübler-Ross, Elisabeth, 821
texts on, 821–823
grieving father, 825
grieving mother
miscarriage, 823
multiple gestation, 824–825
overview, 823–824, 827
stillbirth, 824–826
hospital staff practices
bereavement protocol, 826
cultural considerations, 823
personnel roles, 823–825
talking to grieving families, 826–827
patient resources
books, 828
Internet, 828–829
support groups, 827–828
video, 828
terminology, 821
perineal infiltration, 212–213
perineal/perirectal injuries
avoidance of, 266
common injuries, 265–266
surgical repairs
episiotomy repair, 265, 266–268
internal/external sphincter lacerations, 268–269
rectal mucosa tear, 268
suture material, 269
vaginal lacerations, 266
phenylephrine, 198, 199, 201
physiologic pelvic girdle relaxation. See pelvic relaxation syndrome.
PID (pelvic inflammatory disease), 71–72
PIH. See pregnancy-induced hypertension (PIH) therapy.
Pinard maneuver, 304
Pipelle biopsy, 76–77
Piper forceps, 305
placenta. See also ultrasound, placental.
development/physiology, 145–147
pathology
description at delivery, 160
maternal floor infarction, 161
maturation disorders, 160–161
weight variations, 160
perinatal evaluation, role of, 145
placenta accreta/increta/percreta. See also placental abnormalities.
associations/risk factors, 284
diagnosis, 284, 285
etiology, 152, 284–285
placenta accreta/increta/percreta (Contd.)
hemorrhage risk, 284
infant mortality, 285
management of, 166–167
pathophysiology, 55–56, 150, 285
treatment
conservative management, 285
surgical procedures, 285
vaginal vault/pelvic packing, 286
ultrasound diagnosis, 156–157
placenta delivery. See under labor, third/fourth stage.
placenta increta. See placenta accreta/increta/percreta.
placenta percreta. See placenta accreta/increta/percreta.
placenta previa
etiology/incidence, 55
management
activity restriction, 164
antenatal corticosteroids, 166
artery/vessel ligation, 163–164
bleeding, assessment of, 162–163, 164–165
blood transfusion, 165
cervical cerclage, 166
home-care vs. hospitalization, 165
hysterectomy, 164
incision locations, 163
intraoperative/postpartum hemorrhage, 163
pre-surgery planning, 163, 165
tocolytics, 165–166
pathology, 149
prevalence, 150–152
ultrasound diagnosis
transabdominal ultrasound (TAS), 155
transperineal sonography (TPS), 156
transvaginal ultrasound (TVS), 155–156
placental abnormalities
abnormal trophoblastic invasion, 148–149
epidemiology
marginal placental separation, 150
placenta accreta, 152
placenta previa, 150–152
placental abruption, 152–154
vaginal bleeding, 150
fetal heart rate monitor, 160–169
implantation disruption, 148
intrinsic abnormalities
amniotic band syndrome, 147
chorioangioma, 147
circumvallate placenta, 147
single umbilical arteries (SUA), 148
velamentous insertion, of cord, 147–148
patient/family communication, 170
placenta accreta, 150
placenta previa, 149
placental abruption, 149
preeclampsia/fetal growth restriction, 148–149
placental abnormalities, complications
coagulation disorders, hemorrhagic shock, in newborns, organ damage, respiratory failure/distress, Rh isoimmunization, placental abnormalities, diagnosis fetoscopy, 159
magnetic resonance imaging (MRI), 158–159
patient history, 154
physical examination, 154–155
placental migration, 156
ultrasound scanning
placenta accreta, 156–157
placenta previa, 155–156
placental abruption, 157–158
uses of, 155
placental abnormalities, management of. See also placental abruption.
placenta accreta, 166–167
placenta previa
activity restriction, 164
antenatal corticosteroids, 166
artery/vessel ligation, 163–164
bleeding, assessment of, 162–163, 164–165
blood transfusion, 165
cervical cerclage, 166
home-care vs. hospitalization, 165
hysterectomy, 164
incision locations, 163
intraoperative/postpartum hemorrhage, 163
pre-surgery planning, 163, 165
tocolytics, 165–166
placental abruption
bleeding/blood replacement, 169–170
Couvelaire uterus, 170
evaluation of, 167–168
fetal monitoring, 169
mild/minimally symptomatic cases, 167–168
moderate/severe cases, 168–169
mortality/morbidity, 152–154
pathophysiology, 149
ultrasound diagnosis, 54–55, 157–158
placental examination
benefits of, 289
in obstetric management review, 289
study/storage recommendations, 289–290
placental separation, 259
placental site trophoblastic tumor. See gestational trophoblastic disease.
Planned Parenthood v. Casey abortion, legal decisions in, 867–868
fetal-rights advocacy, 664
polymerase chain reaction (PCR), 25–37
Porro, Eduardo, 9–10
postoperative/postpartum paralysis (POP), 769–770
postpartum hemorrhage (PPH).
See also hemorrhage, operations for; retained placenta; uterine atony; uterine inversion.
causes/signs, 272, 273
diagnosis
blood/arterial pressure, 274
blood loss, 273–274
four-stage classification scheme, 274–275
laboratory tests, 275
urinary output, 274
incidence of, 272
management
compression sutures, 278
embolization, 278
fluid resuscitation, 275
gauze packing, 276–277
hematoma identification, 277–278
hysterectomy, 279
initial/supportive therapy, 275
O’Leary technique, 278
physician assistance, 279
placental examination, 277
subinvolution, 279
surgical control, 278
uterine compression, 277
uterotonic agents, 275
vessel ligation, 278–279
management of, 272
maternal mortality, 272
risk factors, 272–273
Power, R. M. H., 271
Prague maneuver, 303–304.
See also breech presentation, delivery techniques.
preeclampsia/eclampsia
abnormal trophoblastic invasion, 148–149
Doppler flow measurement, 52
drug interactions, 199, 208–209, 210–211
health care education, 680
in hypertensive disorders, 328
IUGR, 146
in maternal mortality, 676–680
and PPH, 272–273
and thrombocytopenia, 211
pregnancy-induced hypertension (PIH) therapy, drug interactions
aspirin, low-dose, 200
cimetidine, 200
hydralazine, 200
labelalox, 200
nitroglycerin, 200
nitroprusside, 200
verapamil, 200
pregnancy termination. See abortion terms.
premature rupture of membranes (PROM), 233, 337
prenatal childhood training (PCT) effectiveness, 202
prenatal genetic program trends
quality assurance, 36
service organization development, 36
technological advances, 25–37
prenatal genetic testing. See also amniocentesis; chorionic villus sampling (CVS); genetic disease.
prenatal genetic testing, multiple gestations
accuracy/sampling error, 35
identification approach, 34
laboratory problems, 35–36
risks
chromosomal aneuploidy, 33–34
miscarriage, 34–35
vs. singleton gestations, 34
selective pregnancy termination, 35
single/dual puncture methods, 34
PROM (premature rupture of membranes), 233, 337
propranolol, 200
Power, R. M. H., 271
Roe v. Wade
abortion, legal decisions in, 866–867
and genetic testing, 177–178
maternal-rights advocacy, 664
wrongful life/wrongful birth, 868–869, 870
ropivacaine, 198
Røsslin, Eucharius, 3
Rousset, Francis, 5
Roussel, François, 5
RU 486 (mifepristone), 133–134
sacroccocygeal teratomas (SCT), 650–651
Sänger, Max, 9–10
Scanzoni, Friedrich Wilhelm, 17
Scanzoni rotation/reverse maneuver, 489–490
SCT (sacroccocygeal teratomas), 650–651
selective feticide, 328, 332, 335, 341–342
selective pregnancy termination, 35
selective reduction, 35, 340–341, 814
910 INDEX

selective trial of labor
in breech presentation, 308
CT pelvimetry, 309
X-ray pelvimetry, 308–309
Sertoli-Leydig cell tumors, 439–440. See also ovarian tumors.
sevoflurane, 197
Shirodkar cerclage, 101–102, 103. See also cervical cerclage.
shoulder dystocia. See also macrosomia; shoulder impaction.
clinical issues
morbidity/mortality, 349
neonatal injury, 349–351
prevalence, 349
clinician/obstetrician role, 348
intrapartum factors
episiotomy, 354
labor abnormalities, 353–354
oxytocin/anesthesia incidence, 354
management/injury profile
disimpaction maneuver study findings, 361
routine cesarean, 361
medical record, 363
occurrence analysis, 349
prediction/prevention, 360
risk factors, predictive value of, 348–349, 354
shoulder dystocia, disimpaction maneuvers
clavicle fracture, 360
posterior arm extraction, 359
rotation maneuvers
fundal pressure in, 359
Rubin’s maneuver, 359
Woods “cork-screw” maneuver, 358–359
simple maneuvers
historical surveys, 357–358
McRoberts maneuver, 358, 361
suprapubic pressure application, 358
Walcher position, 358
Zavanelli maneuver, 360
shoulder dystocia, emergency management plan
anticipation of, 362
assistance, 362
episiotomy, 362–363
obstetric intervention techniques, 363
optimal delivery route determination, 362
shoulder dystocia, medicolegal issues
prevention strategies, 365–366
reasonable conduct, 363–364
standard of care issues, 364–365
shoulder impaction
forces operating in, 355–356
pathophysiology, 354–355, 356
Simpson forceps, 305, 471
Simpson, James Young, 17, 18, 193, 194
single umbilical arteries (SUA), 148
spinal analgesia, 209–210
Spinelli operation, 283
subgaleal/subaponeurotic hemorrhage
diagnosis, 747
morbidity/mortality, 748
prevention of, 747
treatment, 747–748
succinylcholine, 198
sufentanil, 195–196
superficial perineal infection, 287
suppurative fasciitis. See necrotizing fasciitis (NF).
surgery in pregnancy. See also legal considerations, surgical complications; neoplastic diseases.
diagnosis
history/physical examination, 393–394
laboratory data, 395
location/progression of pain, 394
radiography, 395
traumatic injury, 394
surgical technique
drains, 397–398
hemostasis, 396
knot tying, 397
operative incisions, 395–396
skin closure, 397
skin preparation, 396
suture materials, 396–397
wound closure, 396
wound complications
dehiscence/evisceration, 398–399
incisional hernia, 398
integrity, risks to, 398
wound infection
clinical signs/symptoms, 399
etiology, 399
necrotizing fasciitis (NF), 399–400
preventive measures, 399
treatment, 399
surgery in pregnancy, fetal heart rate monitoring
appropriate use of, 880–881
gestation age, role of, 881
labor effects, 881–882
and potential viability, 882–883
protocols, 883
surgical management, 883–885
tocolytic administration, 882
surgery in pregnancy, iatrogenic injuries
avoidance, 406
fetal injuries, 410
gastrointestinal injuries
intestinal tract/bowel lacerations, 406–407
thermal bowel injuries, 407–408
neurologic injuries, 409–410
reporting, 406
reproductive tract injuries, 410
urinary tract injuries, 408–409
surgery in pregnancy, surgical complications
appendicitis
diagnosis, 413–414
epidemiology, 412–413
management, 414–415
gallbladder disease
diagnosis, 411
epidemiology, 410–411
management, 411–412
surgery in pregnancy, systemic complications
deep vein thrombosis (DVT)
antiphospholipid syndrome (APS),
diagnosis, 403–404
Greenfield filter, 405
heparin therapy, 402–403, 404–405
incidence of, 401–402
inherited thrombophilia, 402, 405–406
mechanical intervention, 403
pulmonary embolism, 402
risk factors, 402
therapy, 404
warfarin therapy, 405
febrile morbidity
abdominal abscess, 401
differential diagnosis, 400–401
infection, 401
treatment, 401
symphysiotomy, 7–8, 582–583
synergistic necrotizing cellulitis. See necrotizing fascitis (NF).
syntometrine, 263–264
systemic analgesia, 211–212
TA-CVS (transabdominal biopsy). See under chorionic villus sampling (CVS).
tachycardia/bradycardia. See under fetal monitoring, physiologic principles.
TACIC. See cervicoisthmic cerclage (TACIC)
TAS (transabdominal ultrasound), 155
TC-CVS (transcervical biopsy). See under chorionic villus sampling (CVS).
terbutaline, 199
termination, of pregnancy. See abortion terms.
thiopental, 196–197
thrombocytopenia (TTP)
alloimmune thrombocytopenia (ATTP), 532–533
gestational thrombocytopenia (GTP), 532
immune thrombocytopenia, 532
incidence, 531–532
obstetric intervention recommendations, 533
physiology, 531
thrombophilias. See venous thrombosis (VT).
TLRD (transverse limb reduction defects), 32
tocolytic agents, drug interactions
β2-agonists,
calcium ion antagonists, 199
magnesium sulfate, 199
TPS (transperineal sonography), 156
transabdominal ultrasound (TAS), 155
transperineal sonography (TPS), 156
transvaginal ultrasound (TVS), 155–156
transverse arrest, see under instrumental delivery, instrument application.
transverse limb reduction defects (TLRD), 32
TRAP (twin-reversed arterial perfusion) sequence, 332, 646
trauma, blunt abdominal
fetal risks, 768
incidence of, 768
maternal/fetal assessment, 769
maternal resuscitation, 768
motor vehicle accidents/safety, 768–769
Trautmann, Jeremias, 5
Trendelenburg’s positioning, 102. See also cervical cerclage.
TTP. See thrombocytopenia (TTP).
TTTS. See twin-twin transfusion syndrome (TTTS).
tubal ligation
in cesarean delivery, 583
complications, 588–589
counseling/consent, 584–585
incision, 585
surgical operations
fimbriectomy, 587–588
Irving technique, 586–587
Kroener technique, 587–588
Madlener technique, 585–586
Pomeroy technique, 586
Uchida technique, 587–588
in vaginal delivery, 584
TVS (transvaginal ultrasound), 155–156
twin-reversed arterial perfusion (TRAP) sequence, 332, 646
twin-twin transfusion syndrome (TTTS). See also multiple gestation terms.
alternative interventions, 645–646
amnioreduction, 645
diagnosis, 333
donor risks, 332
fetoscopic laser ablation, 645
management
laser photocoagulation, 334–335
selective fetocide, 335
septostomy, 335
serial amnioreduction, 334
mortality/morbidity, 645
pathophysiology, 332–333, 645
staging, 334
UBF (uterine blood flow), 685–686
ultrasound
expanded use of, 44
fetal weight assessment, 54
gestational age assessment, 53–54
importance of, 62–63
transvaginal approach, 75–76
twin gestation, 58–59
ultrasound, cervical length assessment  
accuracy importance, 44–45  
with digital examination, 46–47  
effacement process, 46–47  
endocervical length, 46  
funneled cervix criteria, 47  
labor outcome prediction, 48  
measurement procedure, 46  
normal lengths, 47  
preterm delivery prediction, 47–48  
transabdominal approach, 45  
transperineal/translabial approach, 46  
transvaginal approach, 45–46

ultrasound, Doppler  
cerebroplacental ratio, 53  
fetal arterial assessment, 51–52, 53  
in intrapartum period, 52–53  
perinatal mortality rates, 52  
properties of, 51  
vascular impedance measurement, 52

ultrasound, fetal position assessment  
fetal occiput position  
identifying landmarks, 58  
as labor management tool, 56–57  
malposition/malrotation, 58  
ultrasound vs. digital examination, 57–58  
fetal presentation, 56

ultrasound, fetal status assessment  
amniotic fluid index (AFI)  
AFI/MVP accuracy comparison, 49  
obtainment method, 49  
oligohydramnios thresholds, 49–50  
polyhydramnios thresholds, 50  
volume as assessment tool, 48–49  
volume/perinatal outcome relationship, 49  
biophysical profile (BPP)  
in intrapartum period, 51  
predictive parameters, 50–51  
score interpretation, 51  
uses of, 50  
fetal occiput position, 58  
maximum vertical pocket (MVP), 49

ultrasound, placental  
diagnosis of abnormalities, 155  
placenta accreta, 55–56  
placenta previa, 55, 155–156  
placental abruption, 54–55

ultrasound, procedure guidance  
endoanal examination, 62  
percutaneous umbilical blood sampling (PUBS), 60–61  
prenatal diagnosis  
amniocentesis, 59  
CVS, 59–60  
as invasive procedure adjunct, 59  
noodle visualization, 60  
retained uterine products, 61–62  
3D/4D techniques, 61
uterine atony
  clinical associations, 279
  treatment, 279–280
uterine blood flow (UBF), 685–686
uterine inversion
  causes/risk factors, 281
  diagnosis, 280–281
  maternal mortality, 281
  types of, 280
uterine inversion, surgical treatment
  abdominal approaches
    Haultain operation, 283
    Huntington procedure, 283
  hydrostatic uterine replacement, 282
  shock, incidence of, 282
  uterine relaxation, 282
uterine relaxation, 215–216, 282
uterotonic agents
  oxytocin
    drug interactions, 199
    in labor physiology, 248
  prostaglandins
    drug interactions, 199
    in labor physiology, 248
vacuum extractors. See also obstetric history,
  vacuum extractors.
  experimental devices, 19
  plastic/disposable devices, 19
  practitioner education, 19–20
vaginal birth after cesarean (VBAC), 511. See also cesarean
delivery and VBAC trial.
vaginal malignancy
  classification/staging, 424
  diagnosis, 423
  epidemiology, 423
  management, 424
  pathology, 423
  prognosis, 424
  Valsalva maneuver, 94
val Roonhuysian instrument(s), 13–14
“vanishing twin” syndrome, 329–330
VBAC (vaginal birth after cesarean), 511. See also cesarean
delivery and VBAC trial.
vecuronium, 198
venous thromboembolism (VTE), 874–875
venous thrombosis (VT)
  diagnosis, 875
  incidence, 874
  pathophysiology, 874–875
  treatment
    alternative treatments, 876
    antepartum concerns, 876
    embolism, prior history of, 877
    pharmacology, 876, 877
    postsurgical care, 876
    pregnancy loss, prior history of, 877
    thrombophilia, lack of, 877
verapamil, 199, 200
very-low-birthweight (VLBW) infants, 316,
  322–323
vulvar malignancy
  classification/staging, 423
  diagnosis, 423
  epidemiology, 423
  management, 423
  pathology, 422–423
wandering, 485
warfarin, 405
Weigart palsy, 350, 756. See birth injuries, fetal.
Wigand-Martin-Winkle maneuver, 303. See also breech
  presentation, delivery techniques.
Williams, J. Whitridge, 355
Wurm technique, 107–108. See also cervical cerclage.